Researchers grew crystals containing actinium and illuminated them with X-rays to learn how the radioactive metal binds with other elements. That information could help design better cancer treatments ...

Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday after the company announced full data results from the pivotal Phase 3 SIERRA trial in patients with active, relapsed or ...

Bristol Myers Squibb’s efforts to diversify its cancer portfolio beyond immunotherapies brought radiopharmaceuticals to its pipeline. Now it’s expanding its radiopharmaceuticals scope to prostate ...

Actinium's SIERRA did not meet secondary endpoint of overall survival on an intent-to-treat basis analysis due to the high crossover rate. Upon concluding its interactions with the FDA, Actinium will ...

Actinium Pharmaceuticals (NYSE:ATNM) added ~13% pre-market Tuesday after announcing its pivotal Phase 3 trial for lead candidate Iomab-B reached the primary endpoint in active relapsed or refractory ...

Oral presentation to highlight Iomab-B's ability to significantly improve overall survival in patients with relapsed or refractory AML with a TP53 mutation Four presentations in total demonstrating ...

- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors - Combination with leading menin ...

NEW YORK, March 29, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced today that it has successfully completed the second module of its previously announced research ...

Actinium's pipeline revitalization has resulted in expanded market opportunities for its first-in-class targeted radiotherapies in myeloid malignancies, solid tumors and cell and gene therapy ...

- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in the tumor ...

Actinium Pharmaceuticals, a New York City-based biopharmaceutical company, named Bernie Cunningham, PhD, executive director of clinical supply chain and logistics, as well as CMS project management.